Product Name | Pomalidomide |
Description |
E3 Ubiquitin Ligase Inhibitor |
Purity | >98% (TLC); NMR (Conforms) |
CAS No. | 19171-19-8 |
Molecular Formula | C13H11N3O4 |
Molecular Weight | 273.2 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | May be dissolved in DMSO (50 mg/ml) |
Source | Synthetic |
Appearance | Yellow powder |
SMILES | C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N |
InChI | InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) |
InChIKey | UVSMNLNDYGZFPF-UHFFFAOYSA-N |
Safety Phrases |
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. Hazard Statements: H301: Toxic if swallowed H312: Harmful in contact with skin H360: May damage fertility or the unborn child H361: Suspected of damaging fertility or the unborn child Precautionary Statement Codes: P201, P202, P264, P270, P280, P281, P301+P310, P302+P352, P308+P313, P312, P321, P322, P330, P363, P405, and P501 |
Cite This Product | Pomalidomide (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-581) |
Alternative Names | 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide |
Research Areas | Angiogenesis Inhibitors, Cancer, Cancer Growth Inhibitors, Cell Signaling, E3 Ubiquitin Ligases, Post-translational Modifications, Ubiquitination |
PubChem ID | 134780 |
Scientific Background | Pomalidomide, a derivative of thalidomide, is an inhibitor TNF-α production (1), enhances the activity of T cells and natural killer cells and enhances antibody- dependent cellular cytotoxicity. It also may inhibit tumor angiogenesis, and promote cell cycle arrest (2). |
References |
1. D'Amato R., Lentzsch S, Anderson K.C. ad Rogers M.S. (2001) Seminars in Oncology. 28(6): 597-601. 2. Fujiwara Y., et al. (2018) Cancer Research. DOI: 10.1158/0008-5472.CAN-18-1781 |
Reviews
There are no reviews yet.